Introduction:

Epigenetic research involves examining the mitotically heritable processes that regulate gene expression, independent of changes in the DNA sequence. Recent technical advances such as whole-genome bisulfite sequencing and affordable epigenomic array-based technologies, allow researchers to measure epigenetic profiles of large cohorts at a genome-wide level, generating comprehensive high-dimensional datasets that may contain important information for disease development and treatment opportunities.

Whole Genome Bisulfite Sequencing (WGBS) is used for detecting methylated cytosines by treating the DNA with sodium bisulfite before sequencing. WGBS is currently considered as the gold standard for studying genome-wide methylation at single base resolution. Methylome analysis is a valuable way to do a range of researches, including studies on gene regulation, cell differentiation, aging, tumorigenesis and phenotypic diversity.

In a NGS seqeuncing project, particular Methyl-Seq, it is very common to fall into the situation of being lack of enough materials for sequencing. Samples that are collected for deep study, such as NGS sequencing, are usually precious with very limited amount available. Sometimes, you have enough materials to start with, however, after several rounds of library preparations, you still can not get NGS datasets with desired quality, and now only very few samples are left for further test. It is the time to contact Complete Omics and learn more about our MyGene™-UltimateSens™ NGS technology, a NGS library construction method WITHOUT EXCESSIVE PCR AMPLIFICATION.

Sample types we accept:

1, Purified DNA samples

2, Cell Lysates and Tissue Lysates

3, Biofluids, such as plasma*, serum*, saliva, tear, etc.

4, FFPE slide/ FFPE extract

5, Fossil

6, Customized sample types (please contact us to discuss)

Collaboration with Columbia University

Mar 30, 2022 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with Professor Kam W. Leong, Samuel Y. Sheng professor of Biomedical Engineering, and his team from…

Read more

Collaboration with Tel Aviv University

Mar 20, 2022 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with Professor Miguel Weil from Department of Cell Research and Immunology at the Tel Aviv University…

Read more

Detecting and Absolutely Quantifying Patient-specific Neoantigens from Limited Input of Biopsy Sample — An Integrated Pipeline for Neoantigen-targeted Cancer Treatments

Neoantigens derived from HERVs represent a new group of cancer therapeutic targets. In a collaborating project, Complete Omics identified and quantified HERVs derived neoantigens and provided solid evidence for developing…

Read more

Some of our impacts